Clinical trial · Observational
Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Deep Learning-Enabled Exploration of Predictive Signatures in a Multicenter Retrospective and Prospective Observational Study Allowing the Analysis of the Aggregation of Multimodal Clinical, Biological, Genomic and Radiomics Data Associated With the Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Predictive models (data collection) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Pembrolizumab monotherapy
- interventionNames
- Other: Predictive models (data collection)
- label
- Chemotherapy and pembrolizumab combination therapy
- interventionNames
- Other: Predictive models (data collection)
- label
- Chemotherapy doublet
- interventionNames
- Other: Predictive models (data collection)
Primary outcomes (1)
- measure
- Treatment response at first evaluation
- timeFrame
- 6-12 weeks after treatment start
- description
- Predict treatment response at first evaluation using baseline data
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult ≥18 years old * Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV) * Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK) * Cohort A: Received first line treatment with pembrolizumab monotherapy * Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy * Cohort C: Received first line treatment with chemotherapy doublet Exclusion Criteria: * Prior anti-cancer therapy for actual stage IV NSCLC * Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging) * Patients participating in other clinical trials that modify the standard of care
References
Publications (0)
Data not yet available